8-K: BillionToOne Reports Strong Q2 2026 Results, Reaffirms Guidance

BillionToOne announced robust second quarter 2026 financial results, with a 64% year-over-year revenue increase and a shift to profitability, while reiterating full-year revenue guidance.

Summary

• BillionToOne reported total revenue of $109.4 million for Q2 2026, a 64% increase from $66.6 million in Q2 2025.
• Prenatal clinical testing revenue grew 55% to $94.2 million, and oncology clinical testing revenue surged 176% to $13.7 million.
• Gross profit margin improved to 70% from 65% year-over-year.
• The company delivered 196,000 tests in Q2 2026, up 35% from 145,000 in Q2 2025.
• Income from operations was $5.5 million, a significant improvement from a $1.6 million operating loss in the prior year's quarter.
• Free cash flow was $5.1 million for the quarter.
• Full-year 2026 revenue guidance remains between $450 million and $465 million, representing 48% to 52% growth.
• The company expects to maintain current profitability levels despite continued investments.

Sentiment

Score: 9

Explanation: StockSavvy.ai views this as a highly positive report, showcasing significant revenue growth, improved profitability, and strategic product expansions.

Positives

• Significant year-over-year revenue growth of 64% to $109.4 million in Q2 2026.
• Strong growth in both prenatal (55%) and oncology (176%) clinical testing revenue.
• Improvement in gross profit margin to 70% from 65% in Q2 2025.
• Increased test volume by 35% year-over-year.
• Achieved income from operations of $5.5 million, a turnaround from an operating loss.
• Generated positive free cash flow of $5.1 million in Q2 2026.
• Reiterated strong full-year revenue guidance of $450 million to $465 million.
• Expansion of Unity Fetal Risk Screen with a 130-gene panel, enhancing market position.

Negatives

• Operating expenses increased by 59% to $71.6 million in Q2 2026 compared to Q2 2025, though this was outpaced by revenue growth.
• Cost-per-test increased slightly due to the faster growth of higher-cost oncology products.

Risks

• Forward-looking statements are subject to risks and uncertainties, including those discussed in the company's SEC filings.
• Actual outcomes could differ materially from forward-looking statements due to factors beyond the company's control.
• The company's ability to continue generating profitability may be impacted by significant continued investments.

Future Outlook

The company reiterates its full-year 2026 revenue guidance to be in the range of $450 million to $465 million, representing 48% to 52% growth over 2025. BillionToOne expects to maintain current profitability levels even with significant continued investments.

Management Comments

• "Our second quarter demonstrated the durability of our model, with our differentiated technology platform, category-defining products, and disciplined execution driving continued growth and profitability," said Dr. Oguzhan Atay, Co-Founder and CEO of BillionToOne.
• "We grew revenue 64% year-over-year to a $438 million annualized run-rate while advancing our product roadmap with the launch of Unity Confirm and the upcoming launches of our expanded Fetal Risk Screen and Northstar Origin."
• "We believe we are still in the earliest chapters of what our smNGS platform can achieve, and we remain relentlessly focused on transforming molecular diagnostics and healthcare."

Industry Context

StockSavvy.ai notes that BillionToOne's strong performance in both prenatal and oncology diagnostics aligns with the broader industry trend of increasing demand for advanced molecular testing solutions. The company's focus on expanding its NIPT panel and developing new features like tissue-of-origin analysis positions it to capture a larger share of a growing market.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, increased profitability, and reiterated positive future outlook.
• Customers: Benefit from expanded and improved diagnostic offerings, such as the larger NIPT panel and new tissue-of-origin feature.
• Employees: Continued growth and profitability may lead to increased job security and potential for expansion.
• Creditors: Improved financial health and positive cash flow strengthen the company's ability to meet its debt obligations.

Next Steps

• Commercial availability of the expanded Unity Fetal Risk Screen on August 17, 2026.
• Commercial availability of the Northstar Origin tissue-of-origin feature on September 1, 2026.
• Continue to operate the business to generate profitability similar to current levels.
• Continue to invest in product development and market expansion.

Key Dates

Recommendation

The filing demonstrates exceptionally strong financial performance with significant revenue growth, improved margins, and a transition to profitability. The company's strategic product expansions and reiterated positive guidance, coupled with a strong cash position, suggest continued upward momentum. This performance, exceeding prior year results and industry expectations, warrants a strong buy recommendation for investors seeking growth in the molecular diagnostics sector.

Keywords

molecular diagnostics, prenatal testing, oncology testing, revenue growth, profitability, financial results, cfDNA testing, NIPT